Accounting & Ind AS Pharma Industry
Contents
1Observations on Implementation of Ind
AS for Pharma
2Recent Accounting Changes
Ind AS 115 – Revenue Recognition
Ind AS 116 – Leases
3 Concluding Remarks
Page 3Accounting & Ind AS – Pharma Industry
MCA Roadmap for Ind AS Implementation
As per MCA notification issued on 16 February 2015, implementation roadmap for Ind AS is as follows:
2015-16 2016-17
April March April March
Financial statements for year ended 31 March 2017
Comparative for 31 March 2016
Opening Balance Sheet 1 April 2015
2016-17 2017-18
April March April March
Financial statements for year ended 31 March 2018
Comparative for 31 March 2017
Opening Balance Sheet 1 April 2016
Phase 1
Phase 2
► Companies listed in or outside India (debt/ equity) with net-worth Rs. 500 Crores or more
► Unlisted companies with net-worth of Rs. 500 Crores or more
► Holding, subsidiary, JV or associate companies of aforesaid companies
► All other listed companies► Unlisted companies with net-worth of Rs.
250 Crores or more► Holding, subsidiary, JV or associate
companies of aforesaid companies
Page 4Accounting & Ind AS – Pharma Industry
Transition to Ind AS*Impact on Headline Numbers
* Source: EY Publication on ‘Ind AS Transition (Journey of Indian Corporates)’ (July 2017)
► Mixed Trend of Impact on various other KPIs such as Revenue, EBITDA and PAT
► Net Worth change driven significantly on account of First Time Transition Choices made
Page 5Accounting & Ind AS – Pharma Industry
Transition to Ind AS – Pharma SectorImpact on Headline Numbers
* Source: EY Publication on ‘Ind AS Transition (Journey of Indian Corporates)’ (July 2017)
Page 6Accounting & Ind AS – Pharma Industry
Transition to Ind AS – Pharma SectorImpact on Headline Numbers
* Source: EY Publication on ‘Ind AS Transition (Journey of Indian Corporates)’ (July 2017)
Page 7Accounting & Ind AS – Pharma Industry
Transition to Ind ASStandards that made their presence felt*
* Source: EY Publication on ‘Ind AS Transition (Journey of Indian Corporates)’ (July 2017)
Ind AS 101 – First Time Transition
Ind AS 109 – Financial Instruments
Ind AS 10 – Events after BS Date
Page 8Accounting & Ind AS – Pharma Industry
Key Impacts noted
Financial Instruments ► Fair value change of derivative and Investments
► Expected credit losses recognized
► Application of EIR
Key AdjustmentsStandards
Revenue Recognition
► Fair valuation of assets & liabilities on acquisition and recognition of intangibles even if not recorded in the books of the seller.
► Impact of reversal of previously amortized goodwill
► Ind AS 101 exemption pertaining to retrospective restatement of past business combinations
Business Combinations
► Netting off of cash discounts & Incentives from Revenue
► Collaboration arrangements, Contract Manufacturing, Out-licensing arrangements
► Profit/Royalty Share arrangements
Others
► Componentization of fixed assets
► Recognition of Outsourcing arrangements as deemed leases.
► Recognition of Intangibles/Brands not recognizable under previous IGAAP
► Change in cost due to fair value accounting of Share based payments
Page 9Accounting & Ind AS – Pharma Industry
Ind AS 116 - Leases
Ind AS 115 – Revenue From Contracts with Customers
1
2
Recognition of Revenue based on the five step model acting as a single source of revenue recognition requirements for all entities in all industries
The Accounting Change
The new standard sets out a comprehensive model for identification of lease arrangements and prescribes single accounting model to be used for all leases with limited exemptions
Page 11Accounting & Ind AS – Pharma Industry
Overview
► On 28 March 2018, MCA notified that Ind AS 115 will be applicable for accounting periods beginning on or after 1 April 2018.
► It replaces all existing Ind AS revenue recognition requirements (Ind AS 11 / 18 / Guidance note on Real estate).
► Ind AS and IFRS revenue standards are substantially aligned, with some limited carve outs.
► The new framework focuses on the performance obligations in the contract and allocating a transaction price to those obligations.
► The new model is a control model, rather than a risk and reward model.
Timeline
First revenue standard on 16 February 2015
Deferred by MCA on 30 March 2016
Full Retrospectiveapplication date
Modified retrospectiveapplication date
2014-15
2015-16
2016-17
2017-18
2018-19
Prior periods presented
Effective
Summary of the model
Core principle: Recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services
Identify the contract(s) with the customer
Identify the performance obligations in the contract
Determine the transaction price
Allocate the transaction price to the performance obligations
Recognize revenue when (or as) each performance obligation is satisfied
01
02
03
04
05
Impact
► It will be necessary to reassess contracts with customers using this five-step model, in order to understand the impact of the new standard.
► Systems and associated business processes are likely to require changes in order to achieve cost-effective compliance.
Step-wise Practical Issues under Ind AS 115
Step 1. Identify
contract
Step 2. Identify
Performance
obligation (PO)
Step 3. Determine
Transaction price
Step 4. Allocate
Transaction priceStep 5. Recognition Others
Contract
Combination
Identification of
contract
Contract
Modification
Multiple Element
Arrangements (PO)
Installation and
Warranty
Material Rights
Free vouchers /
Loyalty points
Right of return
Significant
Financing
Component
Variable
consideration
Non-cash
Consideration
Implied price
concessions
Discounts and
incentives
Estimating
Standalone Selling
Price for allocating
transaction price to
identified PO
Timing of
Recognition of
Revenue – Over time
or point in time
Contract Costs
Principal vs Agent
Presentation /
Disclosures
Transition Method
Licenses
Measure of progress
– Input v/s output
method
Page 14Accounting & Ind AS – Pharma Industry
Global
Scenario
Practical experience - Global / Indian scenario
Indian
Scenario
IFRS 15 became effective globally for periods beginning from 1 January 2018
Ind AS 115 became effective in India for periods beginning from 1 April 2018
Entities mostly likely affected by Changes – Q1 and Q2 impacts
► Construction and engineering entities that enter into contracts that provide for performance obligations, allow for contract modifications or contain significant financing components.
► Retail & consumer and Pharma entities providing rights of return to customers, selling products through distributors or resellers, providing customer options for goods or services and licenses and franchising arrangements.
► Telecommunications entities selling post-paid contracts to customers impacting variable consideration
Entities affected / mostly likely affected by Changes – Q1 impacts
► Real Estate – Many Companies transitioned from POCM to Completed contracts method of revenue recognition like DLF, Prestige Estate Projects, Sobha Ltd
► Pharma – Many Companies did not report major impact on transition, as they transitioned using modified retrospective approach
► Retail - A large retail apparel brand “Shopper’s Stop Limited” reported huge reduction in its revenue on account not meeting ‘transfer of control’ criteria in case of sale or return basis arrangements.
Page 16Accounting & Ind AS – Pharma Industry
Life Science Sector
► Application of Ind AS 115 will require lifesciences entities to use greater judgment.
► The flow of product through the supplychain of a life sciences entity triggers awide range of commercial transactions andevents which fall within the scope of Ind AS115.
► For example, the potential for rebates anddiscounts will impact estimates that arerequired for determining the transactionprice.
► These estimates will need monitoring on anongoing basis to identify any changes tothe transaction price.
Life sciences landscape: why it maybe more challenging
Customers/payers Products Contract type/terms Geography
Arrangements can vary by market
Licences of IP
Milestones
Right of return
Variable consideration
Gross vs. net
Reseller/distributor arrangements
Outcome-based
Collaboration agreements
Cost sharing
Patients
Physician
Hospital
Government agency
Pharmacists
Wholesalers
Specialty distributors
Competitors
Implementing Ind AS 115 – Distribution Channels
Page 17Accounting & Ind AS – Pharma Industry
► Is this a contract with a customer?
► Contracts with oral or implied terms
► Services contract or collaboration agreement?
► Contract combinations
► Products sale contracts including services (medical devices, product or sale support)
► Co-development and co-marketing contracts
► Transportation and insurance as separate POs?
► Principal vs. agent analysis?
Step 1: Identify the contract
► Stand-alone selling price:
► Stand-alone selling prices may not always be observable
► Need to apply appropriate estimation method (if applicable)
Step 4: Allocate transaction price to POs
► When does control transfer?
► Licence agreements (right to access versus right to use)?
► Recognition of sales-based royalties
► Recognition of milestones payments
Step 5: Recognise revenue
Life
sciences
Step 2: Identify the POs
► Variable consideration (e.g., rebates, milestones, performance bonuses, right of returns) and the constraint
► Sales to distributors or resellers and consignment stock
► Financing component (e.g., long-term R&D contracts)
► Consideration paid to customers
► Will your systems and procedures enable you to identify variable consideration at contract inception?
Step 3: Determine the transaction price► Contract costs: costs to obtain the contract
Costs and other issues
Implementing Ind AS 115 – Key Issues
Page 19Accounting & Ind AS – Pharma Industry
Transition choice - Full vs modified retrospective adoption
*Entities may elect either to apply Ind AS 115 only to contracts that are not completed, or to all contracts, including completed contracts, at the date of initial application.
Factors to consider while choosing the approach include:
► The number of contracts to be restated
► The length of contracts: long-term vs short-term
► The ability to obtain historical information
PY(2017-18)
CY(2018-19)
Disclosures
Full retrospective(with optional practical
expedients)
Contracts under new standard Ind AS 115 and Ind AS 8 disclosures apply
Modified retrospective(Cumulative effect at date of
application)Contracts not restated
Existing* and new contracts under new
standard
Existing and new contracts compared using current Ind AS
(e.g., Ind AS 18) in CY
Cu
mu
lati
ve
catc
h-u
p
Contracts restated
Cu
mu
lati
ve
catc
h-u
p
Page 20Accounting & Ind AS – Pharma Industry
Next stepsWhat management can do now
Issues and steps What can management do now?
Gain a general understanding of the standard
► Involve appropriate business unit and finance personnel in Ind AS 115 training sessions
► Stay abreast of latest developments from the FASB, IASB and other regulators
Perform a preliminary assessment of both the accounting and business impact of the standard
► Gather a representative (but judgemental) sample of contracts
► Analyse your commercial relationships with customers over the life cycle of these contracts
► Perform an initial analysis of the accounting rules and develop views about new accounting policy
► Identify both financial and operational risks and judgements (e.g., evaluation of performance obligation, determination of when control is transferred, assessment of the impact of rights to return, warranties and other key contractual terms) by assessing the needs of the business along the contract life cycle
► Include an assessment of necessary disclosures in the financial and operational risk assessment
► Include an assessment of current contract management capabilities in the financial and operational risk assessment
► Form a view of the impact of the accounting changes on key financial ratios and performance, indicators (e.g., gross margins) over the term of the business plan
Interact with the market to exploit both accounting and system solutiondevelopments
► Stay abreast of industry developments and amendments to the standard that may be issued by accounting standard setters
► Initiate discussion with peers on industry-specific revenue recognition issues
► Participate in both sector and generic system development to influence and exploit new solutions
Page 22Accounting & Ind AS – Pharma Industry
Overview
► IASB issued IFRS 16 in January 2016 which replaces the existing IAS 17 for financial periods beginning on or after 1 January 2019.
► ASB of ICAI issued exposure draft on Ind AS 116 Leases on July 18, 2017.
► Lessees will have a single on-balance sheet accounting model for all leases, with exemptions for short-term leases and leases of low-value assets.
► Lessor accounting is substantially unchanged.
► Lessees and lessors will have additional disclosure requirements compared to current accounting.
► The new standard could have broad implications for entities’ finances, operations and EBITDA.
► Implementing the standard could require an entity to develop new processes and controls or adjust existing ones to identify and account for leases.
► New standard is expected to be effective for annual reporting periods beginning on or after 1 April 2019. Early application not permitted.
IFRS 16 to cause an impact on ~$2.86t off-balance sheet Leases over a sample of 14,000 listed companies – as per a study
published by IASB in a publication: ‘Effect Analysis IFRS 16 Leases’
Page 23Accounting & Ind AS – Pharma Industry
MCA issued a Exposure draft on new standard Ind AS 116 Leases. The Ind AS 116 replaced all previous accounting standard on leases Ind AS 17
2019
► Effective date of implementation- 1 April 2019
► Post migration monitoring
► Keeping update with Ind AS 116
2018
2016
► Impact assessment
► Accounting policy adoption
► Single repository for lease contracts
► Data, systems and processes’ compliant
► Reporting and disclosure requirements
► Development of lease strategy
► Start Leases comparative period
Ge
ttin
g In
d A
S 1
16
re
ady
Ind AS 116 - Sector Impact
Sector Level of impact Effort to comply
Telecom H H
Banking M H
Retail H H
Mining H M
Oil and Gas M M
Construction L M
Insurance M L
Heat map
Low
Medium
High
Kickoff Stalled
2018: key year to prepare
Diagnostic
Design & Plan
Application
Percentage of IFRS/US GAAP listed companies that disclose off-balance sheet Leases1
Asia Pacific 43% North America 62% Africa/ Middle East 23%
Latin America 23% Europe 47%
Note: As per a study on Ind AS 116 effects by IASB
Setting the ContextApplying Ind AS 116
Page 24Accounting & Ind AS – Pharma Industry
Property (land, office building, store etc.)Plant and equipment (vehicle, IT assets)Office equipment
Setting the ContextApplying Ind AS 116
MAC issued a new standard Ind AS 116 Leases. The Ind AS 116 replaced all previous accounting standard on leases Ind AS 17.
What is Ind AS 116?
New Leases standard by MCA
April2019
Effective Early application not permitted
Understanding Ind AS 116
Recognise assets and liabilities for most Leases that may currently account for as Operating Leases:
Lessees permitted to chose transition period:• Full retrospective; or• Modified retrospective
Need to review all contracts to identify the impact areas
Key Judgements and estimates
► Is it a lease?
► Are there non-lease components in the contract?
► Should the practical expedient for short-term leases be considered?
► What is the lease term, considering renewal, termination and purchase options?
► Are there variable lease payments and residual value guarantees?
► What is the lease classification?
► What is the discount rate?
► Does the transaction qualify for sale-leaseback accounting?
► Which transition approach to be adopted in IFRS – full retrospective or modified retrospective?
Identifying Lease contracts
The contract represents or contains a Lease The contract does not represent or contain a Lease
Yes
Customer
YesNo
Yes
Neither; how and what purpose is predetermined Yes
Supplier
No
No
NoNo
Is there an identified asset? 2
Does the customer or supplier have right to direct, how and for what purpose the identified asset is used throughout the period of use?
Does the customer have right to obtain substantially all economic benefits from the use of identified asset throughout the period of use?
Does the customer have right to operate the asset throughout the period of use, without the supplier having the right to change those operating instructions?
Did the customer design the asset (or specific aspects of the asset) in a way that predetermines how and for what purpose the asset will be used throughout the period of use?
Page 25Accounting & Ind AS – Pharma Industry
Recognition and measurement
► A lessee applies a single lease accounting model under which it recognises all major leases on-balance sheet
Balance sheet
Asset= ‘Right-of-use’ of underlying asset
Liability = Obligation to make lease payments
Profit and Loss
Lease expense = Depreciation + Interest
Consider exemptions - Short-term lease and lease of low-value assets
Page 26Accounting & Ind AS – Pharma Industry
Lessee accounting: Initial measurement– ROU
Lease liability
Initial direct costs
Estimated costs to dismantle, remove or restore, measured In accordance with Ind AS 37
Prepaid lease payments (eg. Deposit)
Lease incentives Received
Right-of-use-asset
Page 27Accounting & Ind AS – Pharma Industry
Impact on financials
► Companies with operating leases will appear to be more asset-rich, but also more heavily indebted
Asset Liability
Impact on balance sheet
Impact on statement of profit and loss
► Total lease expense will be front-loaded even when cash rentals are constant
Depreciation Interest
Cash rental payments
Page 28Accounting & Ind AS – Pharma Industry
Impact on financials ratios
GearingEBITDA
EPS (in early years)
Net assets Interest cover
Total assets
RatiosProfit/loss Balance sheet
Practical Implementation Issues
Non-lease components
Separate non-lease components (e.g. services)
Practical expedient (policy) –account all as a lease
1Combining contracts
Negotiated as packaged with single objective OR
Price of contract depends on price / performance of another
2Sub leases
Generally treated as two leases unless meet contract combination requirements
3Measuring variable payments
Lessee shall include variable payments as part of lease liability
Lessor shall include variable payments as part of rental income
Intra-group leases
To be evaluated for standalone financial statements
54Initial Direct Costs
To be included as part of the right of use asset and
6
Page 31Accounting & Ind AS – Pharma Industry
Lease implementation journey
Future state
Current state
1. Understand current state of leasing and revenue activities
(e.g., lease procurement, revenue contracts administration, and accountingand reporting)
2. Identify changes resulting from the new standards (e.g., data gaps, processes, controls, systems and tax)
5. Transition to the new standards for both leasesand revenue recognition
3. Design solution for accounting change
(e.g., new accounting policies, processes, controls and
systems) to capture new lease data requirements
and understand financial statement impact
4. Implement new accounting policies, processes, controls and systems, as well
as changes to financial statements and disclosures
Page 32Accounting & Ind AS – Pharma Industry
Key Disclosures - Lessee
Quantitative disclosures
Income statement Balance sheet
Financial Statements
Cash flow statement
►Maturity analysis of lease l iabi l i t ies
►Carrying amount of r ight -of-use assets (by class)
► Amortization expense for right-of-use assets
► Short-term lease expense
► Small ticket lease expense
► Variable lease expense
► Interest on lease liabilities
► Income from subleases
► Sale and lease back
► Cash outflow for leases
► Additions to right-of-use assets
Qualitative disclosures
► Nature of lessee's leasing activities
► Future cash outflows to which the lessee is potentially exposed that are not reflected in the measurement of liabilities:
► Variable lease payments
► Extension and termination options
► Residual value guarantees
► Leases not yet commenced which the lessee is committed
► Restrictions or covenants imposed by leases
► Sale and lease back transactions
Page 33Accounting & Ind AS – Pharma Industry
Transition date – Retrospective Vs Modified approach optionLessees are permitted to choose between two transition approaches applied consistently to all leases
► Full retrospective► Modified retrospective
Retrospective application or modified approach?
Option 2A –
► Measure asset as if Ind AS 116 had been applied from lease commencement (but using incremental borrowing rate at date of transition)
Option 1 – Retrospective
► Restate comparatives as if Ind AS 116 always applied
Option 2 – Modified (Do not change comparative FS)
► Difference between asset and liability recognised in opening RE at transition date.
► Operating Leases:
► Calculate present value of remaining lease payments for existing operating leases using incremental borrowing rate at date of transition.
► Choose how to measure ROU asset on lease-by-lease basis:
Option 2B –
► Measure asset at amount equal to liability (adjusted for accruals and prepayments)